Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03282981 · ClinicalTrials.gov registry record · Phase 3
Beta Adrenergic Antagonist for the Healing of Chronic DFU
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
NCT03282981: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT03282981 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03282981, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
Study Summary
One in four Veterans is affected by diabetes and will develop a diabetic foot ulcer. Diabetic ulcers are very challenging to manage and are the most common cause of leg amputation. Many advanced treatments are expensive and difficult to use in the clinic or at home. Those newer therapies have shown little success in healing diabetic foot wounds. The investigators' laboratory and animal work has suggested that a safe medication, currently used as an eye drop for treatment of glaucoma, can heal these ulcers. The investigators are proposing to test this drop (timolol) directly on the surface of the foot ulcer to see if can improve healing faster than the current standard of care. To do this, the investigators propose a "randomized controlled trial" with two groups of patients with diabetic foot ulcers: one will receive standard of care with timolol while the other will receive standard of care with a gel (hydrogel, as placebo medicine).
Interventions
- DRUG Timolol
- DRUG Non biologically active gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03282981
The ClinicalTrials.gov registry entry for NCT03282981 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Timolol is the first listed.
NCT03282981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03282981 about?
NCT03282981 is a clinical study titled "Beta Adrenergic Antagonist for the Healing of Chronic DFU". One in four Veterans is affected by diabetes and will develop a diabetic foot ulcer. Diabetic ulcers are very challenging to manage and are the most common cause of leg amputation. Many advanced treatments are expensive and difficult to use in the clinic or at home. Those newer therapies have shown ...
What is the current status of trial NCT03282981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2018-07-24. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT03282981?
The interventions under investigation include: Timolol (DRUG), Non biologically active gel (DRUG).
Who is sponsoring clinical trial NCT03282981?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.